BR112014015405A2 - novo anticorpo ctgf anti-humano - Google Patents
novo anticorpo ctgf anti-humanoInfo
- Publication number
- BR112014015405A2 BR112014015405A2 BR112014015405A BR112014015405A BR112014015405A2 BR 112014015405 A2 BR112014015405 A2 BR 112014015405A2 BR 112014015405 A BR112014015405 A BR 112014015405A BR 112014015405 A BR112014015405 A BR 112014015405A BR 112014015405 A2 BR112014015405 A2 BR 112014015405A2
- Authority
- BR
- Brazil
- Prior art keywords
- human ctgf
- ctgf antibody
- human
- antibody
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 | ||
| PCT/JP2012/083206 WO2013094723A1 (ja) | 2011-12-22 | 2012-12-21 | 新規抗ヒトｃｔｇｆ抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014015405A2 true BR112014015405A2 (pt) | 2017-06-13 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014015405A BR112014015405A2 (pt) | 2011-12-22 | 2012-12-21 | novo anticorpo ctgf anti-humano |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (https=) |
| EP (1) | EP2796550B1 (https=) |
| JP (1) | JP6040943B2 (https=) |
| KR (1) | KR20140107507A (https=) |
| CN (1) | CN104011206B (https=) |
| AR (1) | AR089425A1 (https=) |
| BR (1) | BR112014015405A2 (https=) |
| CA (1) | CA2859627A1 (https=) |
| EA (1) | EA029290B1 (https=) |
| ES (1) | ES2665851T3 (https=) |
| IN (1) | IN2014CN04615A (https=) |
| MX (1) | MX345019B (https=) |
| PL (1) | PL2796550T3 (https=) |
| PT (1) | PT2796550T (https=) |
| TW (1) | TW201333034A (https=) |
| WO (1) | WO2013094723A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CN115925926A (zh) * | 2019-06-04 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 抗结缔组织生长因子抗体及其应用 |
| CN116391041A (zh) * | 2020-12-03 | 2023-07-04 | 江苏恒瑞医药股份有限公司 | 一种含抗结缔组织生长因子抗体的药物组合物 |
| JPWO2023238845A1 (https=) | 2022-06-07 | 2023-12-14 | ||
| TW202434302A (zh) | 2022-10-31 | 2024-09-01 | 日商安斯泰來製藥股份有限公司 | 包含類鐸受體７／８雙重促效劑化合物之抗體藥物複合體 |
| TW202502816A (zh) * | 2023-03-10 | 2025-01-16 | 大陸商上海濟煜醫藥科技有限公司 | 一種靶向ｃｔｇｆ的抗體或其抗原結合片段及其應用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| WO1994020632A1 (fr) | 1993-03-11 | 1994-09-15 | Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute | Anticorps monoclonal dirige contre le vih |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| WO1999033878A1 (en) * | 1997-12-25 | 1999-07-08 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| DK1140969T3 (da) | 1998-12-14 | 2007-09-17 | Univ Miami | Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja not_active Ceased
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2796550B1 (en) | 2018-02-28 |
| EP2796550A1 (en) | 2014-10-29 |
| ES2665851T3 (es) | 2018-04-27 |
| EA029290B1 (ru) | 2018-03-30 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| KR20140107507A (ko) | 2014-09-04 |
| PT2796550T (pt) | 2018-04-18 |
| MX2014007681A (es) | 2014-11-25 |
| AR089425A1 (es) | 2014-08-20 |
| EA201491240A1 (ru) | 2014-11-28 |
| EP2796550A4 (en) | 2015-08-19 |
| US9587015B2 (en) | 2017-03-07 |
| TW201333034A (zh) | 2013-08-16 |
| MX345019B (es) | 2017-01-11 |
| CN104011206B (zh) | 2017-03-08 |
| JP6040943B2 (ja) | 2016-12-07 |
| CN104011206A (zh) | 2014-08-27 |
| WO2013094723A1 (ja) | 2013-06-27 |
| IN2014CN04615A (https=) | 2015-09-18 |
| CA2859627A1 (en) | 2013-06-27 |
| US20140343258A1 (en) | 2014-11-20 |
| PL2796550T3 (pl) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014015405A2 (pt) | novo anticorpo ctgf anti-humano | |
| BR112013024923A2 (pt) | novo anticorpo receptor de il-23 anti-humano | |
| EA201490433A1 (ru) | Новое антитело против ngf человека | |
| CL2012003283A1 (es) | Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| UA110358C2 (en) | Molecules of antibody binding il-17a and il-17f | |
| CL2012000229A1 (es) | Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular. | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| ECSP12011584A (es) | Anticuerpos anti-vegf y sus usos | |
| UA114891C2 (uk) | ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| PE20141659A1 (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
| EA200900037A1 (ru) | Моноклональные антитела против интерлейкина-6 (il-6) и их применение | |
| BR112016014920A2 (pt) | novo anticorpo anti-bdca-2 humano | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| EA201491656A1 (ru) | Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения | |
| BRPI0812248B8 (pt) | estradômero agrupado | |
| EA201000559A1 (ru) | Композиции и способы применения антител к склеростину | |
| BR112012021327B8 (pt) | anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo. | |
| CR20110526A (es) | Anticuerpos anti - tnf - alfa y sus usos | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 |